26
Participants
Start Date
January 15, 2021
Primary Completion Date
January 19, 2023
Study Completion Date
January 19, 2023
Posoleucel (ALVR105)
Administered as 2-4 milliliter infusion
Weill Cornell Medical College, New York
Stony Brook University Hospital Cancer Center, Stony Brook
Childrens National Medical Center, Northwest Rectangle
University of Maryland Medical Center, Baltimore
The Johns Hopkins Hospital, Baltimore
University of Virginia, Charlottesville
University of Alabama at Birmingham, Birmingham
Nationwide Children's Hospital, Columbus
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
University of Minnesota, Minneapolis
Children's Mercy Kansas City, Kansas City
University of Kansas Hospital, Westwood
Children's Medical Center Dallas, Dallas
City of Hope National Medical Center, Duarte
University of California, San Francisco Medical Center, San Francisco
Fred Hutchinson Cancer Research Center, Seattle
Lead Sponsor
AlloVir
INDUSTRY